What docs can't afford to overlook amid the GLP-1 boom

The era of glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped obesity management in primary care and specialty clinics alike.

As these therapies gain widespread use beyond traditional settings, shifting from diabetes, to obesity, to preventive medicine, new questions are emerging, particularly around unexpected health impacts (from "Ozempic vulva" to hair loss).

A lot of the side effects surprising patients can primarily be boiled down to a single issue: Nutritional deficiencies related to changes in eating habits. It begs the question: Should supplementation be better emphasized in GLP-1 protocol? ^[]

Appetite suppression, reduced intake—and nutrient gaps?

GLP-1 therapies are highly effective for weight management. ^[] But this creates a potential for suboptimal intake of essential nutrients if patients are not eating a balanced, nutrient-dense diet.

The supplement marketplace—a clinician’s reality check

In response to these concerns, the marketplace has exploded with “GLP-1 support supplements”—products claiming to prevent muscle loss, shore up nutrient status, or otherwise enhance outcomes on these drugs. ^[]

But evidence for these formulations is often weak, selective, or extrapolated from non-GLP-1 populations. Consider the following:

• Many products include ingredients like biotin, touted for skin, hair, or metabolic benefits, despite little evidence that they address the specific nutritional changes seen with appetite-suppressing therapies. ^[]

• A growing body of consumer supplements is not regulated as rigorously as pharmaceuticals, meaning quality, purity, and even labeling accuracy can be highly variable. ^[]

The bottom line: Routine prescription of pricey, branded “GLP-1 supplements” is not backed by solid data.

Practical guidance for clinicians

If your patient on a GLP-1 agonist asks, “Do I need supplements?” here are practical steps grounded in evidence and clinical judgment:

1. Assess dietary intake first

A simple 24-hour recall or food frequency questionnaire can flag gaps in nutrient intake. Reduced eating does not automatically mean deficiency—it depends on what patients are eating. Encourage nutrient-dense whole foods first. ^[]

2. Ensure targeted testing, not blanket supplementation

Rather than empirically prescribing broad multivitamins or specialty products, reserve supplements for patients with confirmed deficiencies (eg, documented low vitamin D). This aligns with general nutrition science: Supplements are most useful when there’s a clear need. ^[]

3. Be skeptical of marketing claims

Be honest with patients about products marketed specifically for “GLP-1 support.” Explain that most have limited or no evidence showing they address the issues these drugs raise—and that high price doesn’t guarantee high quality. ^[]

4. Coordinate with dietitians

Complex nutritional concerns—especially in patients with comorbidities or those reporting food intolerances—benefit from partnership with registered dietitians. They can help tailor dietary plans and identify when supplementation is appropriate.

However, “only 20% of GLP-1 users are ever referred to a dietitian,” said Jackie Brenner, a fourth-year MD/MPH student, in an Instagram Reel.

What this means for your clinic

This conversation underscores a larger trend: Your patients are not just showing up for injections—they’re showing up with questions shaped by social media, online marketing, and wellness culture.

Rather than defaulting to supplements, emphasize individualized care, evidence-based nutrition, and thoughtful monitoring.

A nuanced approach will serve both your patients’ health and your clinic’s reputation as a source of trusted, scientific guidance in an era of rapid change.